Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555449 · ClinicalTrials.gov registry record · Phase 1
A Study of [¹⁴C]-LY3202626 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02555449: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02555449 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02555449, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \[¹⁴C\] gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. Participants will stay at a clinical research unit (CRU). The study will last about 28 days (check in to follow-up) for each participant. This study is for research purposes only and is not intended to treat any medical condition.
Primary Outcome
Fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered.
Interventions
- DRUG [¹⁴C]-LY3202626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
What the finished NCT02555449 record still lists
NCT02555449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3202626 is the first listed.
NCT02555449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02555449 about?
NCT02555449 is a clinical study titled "A Study of [¹⁴C]-LY3202626 in Healthy Male Participants". The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \[¹⁴C\] gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. Participant...
What is the current status of trial NCT02555449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-09. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02555449?
The interventions under investigation include: [¹⁴C]-LY3202626 (DRUG).
Who is sponsoring clinical trial NCT02555449?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02555449's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia